Welcome to BMS Science
BMS Science is a fast and easy way to find our recruiting and soon-to-be recruiting trials. Search clinical trials simply by entering a disease area of interest and/or a location.Search BMS Recruiting Clinical Trials
0 trials
Status
- Not Yet Recruiting
- Recruiting
Phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
Clinical trial information is sourced from ClinicalTrials.gov. Information is updated manually as the clinical trials are published. The efficacy and safety of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
Interested in looking outside of BMS-sponsored trials?
Visit BolderScience.com to search all worldwide trials.
CardiovascularGenetic Dilated Cardiomyopathy
Danicamtiv
Myosin Activator
Area of Research: Genetic Dilated Cardiomyopathy
Phase 2
Expand All Displaying 5 of 11
Genetic Dilated Cardiomyopathy
No trials are available at this time. Check back for updates.
Heart Failure
Mavacamten
Selective Cardiac Myosin Inhibitor
Area of Research: Heart Failure With Preserved Ejection Fraction
Phase 2
Expand All Displaying 5 of 11
Heart Failure
No trials are available at this time. Check back for updates.
Venous Thromboembolism Treatment (Pediatric)
ApixabanFactor Xa Inhibitor
Area of Research: Pediatric Subjects Requiring Anticoagulation for the Treatment of a VTE
Phase 4
Expand All Displaying 5 of 11
Venous Thromboembolism Treatment (Pediatric)
No trials are available at this time. Check back for updates.
Fibrotic DiseasesNonalcoholic Steatohepatitis
BMS-986263HSP47 siRNA
Area of Research: Compensated Cirrhosis From NASH
Phase 2
Expand All Displaying 5 of 11
Nonalcoholic Steatohepatitis
No trials are available at this time. Check back for updates.
Pulmonary Fibrosis
No trials are available at this time. Check back for updates.
HematologyAcute Myeloid Leukemia
CC-90009 + BH3-mimetic + Azacitidine
GSPT1 CELMoD + BH3-mimetic + DNA Methyltransferase Inhibitor
Area of Research: AML
Phase 1/2
CC-95251 ± DNA Methyltransferase Inhibitor
Anti–SIRP⍺ ± DNA Methyltransferase Inhibitor
Area of Research: AML
Phase 1
Oral Azacitidine + BH3-mimetic
DNA Methyltransferase Inhibitor + BH3-mimetic
Area of Research: AML
Phase 1
Oral Azacitidine
DNA Methyltransferase Inhibitor
Area of Research: Maintenance of AML After Complete Remission
Phase 2
Expand All Displaying 5 of 11
Acute Myeloid Leukemia
No trials are available at this time. Check back for updates.
Beta-Thalassemia
Luspatercept-aamt
Erythroid Maturation Agent
Area of Research: Long-term Safety
Phase 3
Luspatercept-aamt
Erythroid Maturation Agent
Area of Research: Safety and PK in pediatric patients with regular RBCTs in Beta-Thalassemia
Phase 2
Expand All Displaying 5 of 11
Beta-Thalassemia
No trials are available at this time. Check back for updates.
Chronic Lymphocytic Leukemia
Liso-cel ± BH3-mimetic
CD-19 CAR T ± BH3-mimetic
Area of Research: R/R CLL/SLL
Phase 1/2
Liso-cel ± BTK Inhibitor
CD-19 CAR T ± BTK Inhibitor
Area of Research: R/R CLL/SLL
Phase 1/2
Expand All Displaying 5 of 11
Chronic Lymphocytic Leukemia
No trials are available at this time. Check back for updates.
Hematologic Malignancies
CC-95251 + Anti–CD-20
Anti–SIRPα + Anti–CD-20
Area of Research: Advanced Hematologic Cancers
Phase 1
CC-95251 + EGFR Inhibitor
Anti–SIRPα + EGFR Inhibitor
Area of Research: Advanced Hematologic Cancers
Phase 1
Gene-modified (GM) T-cell Therapy
Gene-modified (GM) T-cell Therapy
Area of Research: Long-term Safety
Phase 2/3
Expand All Displaying 5 of 11
Hematologic Malignancies
No trials are available at this time. Check back for updates.
Lymphoma
CC-97540 followed by chemotherapy
CD-19 NEX T
Area of Research: DLBCL: 3L+
Phase 1
CC-99282 + Anti–CD-20
A/I Immunomodulatory Agent + Anti–CD-20
Area of Research: R/R CLL/SLL
Phase 1
CC-99282 + Chemotherapy + Steroid
A/I Immunomodulatory Agent + Chemotherapy + Steroid
Area of Research: Aggressive B-cell Lymphoma
Phase 1
CC-99282 ± Anti–CD-19
A/I Immunomodulatory Agent ± Anti–CD-19
Area of Research: R/R NHL
Phase 1
CC-99282 ± Anti–CD-20
A/I Immunomodulatory Agent ± Anti–CD-20
Area of Research: R/R NHL
Phase 1
CC-99282 ± EZH2 Inhibitor
A/I Immunomodulatory Agent ± EZH2 Inhibitor
Area of Research: R/R NHL
Phase 1
Iberdomide + Anti–CD-20
Immunomodulatory Agent + Anti–CD-20
Area of Research: MZL: 3L+
Phase 1
Iberdomide + Anti–CD-20
Immunomodulatory Agent + Anti–CD-20
Area of Research: NHL: 3L+
Phase 1
Iberdomide + Chemotherapy + Steroid
Immunomodulatory Agent + Chemotherapy + Steroid
Area of Research: Aggressive B-cell Lymphoma
Phase 1
Liso-cel + Anti–PD-1
CD-19 CAR T + Anti–PD-1
Area of Research: 3L+ DLBCL
Phase 1/2
Liso-cel + BTK Inhibitor
CD-19 CAR T + BTK Inhibitor
Area of Research: 3L+ DLBCL
Phase 1/2
Liso-cel + CC-99282
CD-19 CAR T + A/I Immunomodulatory Agent
Area of Research: 3L+ DLBCL
Phase 1/2
Liso-cel + Chemotherapy
CD-19 CAR T + Chemotherapy
Area of Research: Pediatric R/R B-ALL and B-NHL
Phase 1/2
Liso-cel + Iberdomide
CD-19 CAR T + Immunomodulatory Agent
Area of Research: 3L+ DLBCL
Phase 1/2
Liso-cel + Relatlimab ± Nivolumab
CD-19 CAR T + Anti–LAG-3 ± Anti–PD-1
Area of Research: 3L+ DLBCL
Phase 1/2
Nivolumab + Relatlimab
Anti–PD-1 + Anti–LAG-3
Area of Research: R/R HL and R/R NHL
Phase 1/2
Expand All Displaying 5 of 11
Lymphoma
No trials are available at this time. Check back for updates.
Multiple Myeloma
CC-92480 + Anti–CD-38 + Dexamethasone
A/I Immunomodulatory Agent + Anti–CD-38 + Steroid
Area of Research: R/R MM and NDMM
Phase 1/2
CC-92480 + Elotuzumab + DexamethasoneA/I Immunomodulatory Agent + Anti-SLAMF7 + Steroid
Area of Research: R/R MM and NDMM
Phase 1/2
CC-92480 + Proteasome Inhibitor + Dexamethasone
A/I Immunomodulatory Agent + Proteasome Inhibitor + Steroid
Area of Research: R/R MM and NDMM
Phase 1/2
CC-92480 ± Dexamethasone
A/I Immunomodulatory Agent ± Steroid
Area of Research: R/R MM
Phase 1/2
CC-98633 followed by chemotherapy
BCMA NEX T
Area of Research: R/R MM: 4L+
Phase 1
Iberdomide + Anti–CD-38 + Dexamethasone
Immunomodulatory Agent + Anti–CD-38 + Steroid
Area of Research: R/R MM: 2L-3L
Phase 3
Iberdomide + Dexamethasone + Anti–CD-38
Area of Research: ASCT-ineligible NDMM
Phase 1/2
Iberdomide + Dexamethasone + Anti–CD-38
Immunomodulatory Agent + Steroid + Anti–CD-38
Area of Research: R/R MM
Phase 1/2
Iberdomide + Dexamethasone + Proteasome Inhibitor
Area of Research: ASCT-ineligible NDMM
Phase 1/2
Iberdomide + Dexamethasone + Proteasome Inhibitor
Immunomodulatory Agent + Steroid + Proteasome Inhibitor
Area of Research: NDMM
Phase 1/2
Iberdomide + Dexamethasone + Proteasome Inhibitor
Area of Research: R/R MM
Phase 1/2
Iberdomide ± Dexamethasone
Immunomodulatory Agent ± Steroid
Area of Research: R/R MM
Phase 1/2
Ide-cel + Iberdomide ± Dexamethasone
BCMA CAR T + Immunomodulatory Agent ± Steroid
Area of Research: R/R MM
Phase 1/2
Ide-cel + Pomalidomide + Anti–CD-38 + Dexamethasone
BCMA CAR T + Immunomodulatory Agent + Anti–CD-38 + Steroid
Area of Research: R/R MM
Phase 1/2
Ide-cel + Pomalidomide + Proteasome Inhibitor + DexamethasoneBCMA CAR T + Immunomodulatory Agent + Proteasome Inhibitor + Steroid
Area of Research: R/R MM
Phase 1/2
Expand All Displaying 5 of 11
Multiple Myeloma
No trials are available at this time. Check back for updates.
Myelodysplastic Syndromes
CC-95251 ± DNA Methyltransferase Inhibitor
Anti–SIRP⍺ ± DNA Methyltransferase Inhibitor
Area of Research: MDS
Phase 1
Luspatercept-aamt
Erythroid Maturation Agent
Area of Research: Anemia Due to MDS; ESA-naïve
Phase 3
Luspatercept-aamt
Erythroid Maturation Agent
Area of Research: Anemia Due to Transfusion-dependent MDS-RS
Phase 2
Luspatercept-aamt
Erythroid Maturation Agent
Area of Research: Long-term Safety
Phase 3
Expand All Displaying 5 of 11
Myelodysplastic Syndromes
No trials are available at this time. Check back for updates.
Myelofibrosis
BMS-986158 ± Fedratinib
BETi ± JAK2 Inhibitor
Area of Research: DIPSS–intermediate- or High-risk Myelofibrosis
Phase 1/2
BMS-986158 ± JAK Inhibitor
BETi ± JAK Inhibitor
Area of Research: DIPSS–intermediate- or High-risk Myelofibrosis
Phase 1/2
Fedratinib
JAK2 Inhibitor
Area of Research: PMF, Post-PV MF, Post-ET MF
Phase 3
Phase 1/2
Luspatercept-aamt
Erythroid Maturation Agent
Area of Research: Long-term Safety
Phase 3
Luspatercept-aamt
Erythroid Maturation Agent
Area of Research: MPN-associated MF
Phase 3
Expand All Displaying 5 of 11
Myelofibrosis
No trials are available at this time. Check back for updates.
ImmunologyAnkylosing Spondylitis
No trials are available at this time. Check back for updates.
Atopic Dermatitis
BMS-986166
S1PR1 Modulator
Area of Research: Moderate to Severe Atopic Dermatitis
Phase 2
Branebrutinib
BTK Inhibitor
Area of Research: Moderate to Severe Atopic Dermatitis
Phase 2
Expand All Displaying 5 of 11
Atopic Dermatitis
No trials are available at this time. Check back for updates.
Crohn's Disease
Deucravacitinib
TYK2i
Area of Research: Moderate to Severe Crohn's Disease
Phase 2
Expand All Displaying 5 of 11
Crohn's Disease
No trials are available at this time. Check back for updates.
Cutaneous Lupus Erythematosus
No trials are available at this time. Check back for updates.
Eosinophilic Esophagitis
No trials are available at this time. Check back for updates.
Multiple Sclerosis
No trials are available at this time. Check back for updates.
Psoriasis
Deucravacitinib
TYK2i
Area of Research: Moderate to Severe Plaque Psoriasis
Phase 3
Expand All Displaying 5 of 11
Psoriasis
No trials are available at this time. Check back for updates.
Psoriatic Arthritis
Deucravacitinib
TYK2i
Area of Research: Active PsA, Naïve to Biologic DMARDs or Previously Received Treatment With TNFα Inhibitor
Phase 3
Deucravacitinib
TYK2i
Area of Research: Active PsA, Naïve to Biologic DMARDs
Phase 3
Expand All Displaying 5 of 11
Psoriatic Arthritis
No trials are available at this time. Check back for updates.
Rheumatoid Arthritis
Abatacept + Chemotherapy ± DMARD
Immunomodulatory Agent
Area of Research: Early, Seropositive RA
Phase 3
Branebrutinib + Abatacept
BTK Inhibitor + Immunomodulatory Agent
Area of Research: Rheumatoid Arthritis
Phase 2
Expand All Displaying 5 of 11
Rheumatoid Arthritis
No trials are available at this time. Check back for updates.
Sjögren Syndrome
No trials are available at this time. Check back for updates.
Systemic Lupus Erythematosus
Afimetoran
TLR 7/8 Inhibitor
Area of Research: Systemic Lupus Erythematosus
Phase 2
Branebrutinib
BTK Inhibitor
Area of Research: Systemic Lupus Erythematosus
Phase 2
Expand All Displaying 5 of 11
Systemic Lupus Erythematosus
No trials are available at this time. Check back for updates.
Ulcerative Colitis
Deucravacitinib
TYK2i
Area of Research: Moderate to Severe Ulcerative Colitis
Phase 2
Ozanimod
S1PR1 Modulator
Area of Research: Moderate to Severe Active Ulcerative Colitis
Phase 3
Ozanimod
S1PR1 Modulator
Area of Research: Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Phase 2/3
Expand All Displaying 5 of 11
Ulcerative Colitis
No trials are available at this time. Check back for updates.
Solid TumorsBladder
Nivolumab + Chemotherapy
Anti–PD-1 + Chemotherapy
Area of Research: Perioperative MIBC
Phase 3
Nivolumab + Ipilimumab
Anti–PD-1 + Anti–CTLA-4 or Chemotherapy
Area of Research: 1L Unresectable or Metastatic Urothelial Carcinoma
Phase 3
Expand All Displaying 5 of 11
Bladder
No trials are available at this time. Check back for updates.
Colorectal
Nivolumab + MEK Inhibitor ± Ipilimumab
Anti–PD-1 + MEK Inhibitor ± Anti–CTLA-4
Area of Research: 2L+ mCRC
Phase 1/2
Nivolumab ± Ipilimumab
Anti–PD-1 ± Anti–CTLA-4
Area of Research: 1L+ Recurrent or Metastatic MSI-H/dMMR CRC
Phase 3
Nivolumab ± Relatlimab
Anti–PD-1 ± Anti–LAG-3
Area of Research: 2L+ mCRC
Phase 3
Expand All Displaying 5 of 11
Colorectal
No trials are available at this time. Check back for updates.
Glioblastoma
CC-90010 + Chemotherapy ± RT
BET Inhibitor + Chemotherapy ± RT
Area of Research: Newly Diagnosed Glioblastoma
Phase 1
Expand All Displaying 5 of 11
Glioblastoma
No trials are available at this time. Check back for updates.
Hepatocellular Carcinoma
Nivolumab ± Relatlimab
Anti–PD-1 ± Anti–LAG-3
Area of Research: Advanced HCC
Phase 2
Expand All Displaying 5 of 11
Hepatocellular Carcinoma
No trials are available at this time. Check back for updates.
Lung
Neoadjuvant Nivolumab + Chemotherapy, Followed by Adjuvant Nivolumab
Anti–PD-1 + Chemotherapy
Area of Research: Resectable NSCLC
Phase 3
Nivolumab + Chemotherapy + RT, Followed by Maintenance Nivolumab ± Ipilimumab
Anti–PD-1 ± Anti–CTLA-4
Area of Research: Locally Advanced NSCLC Amenable to cCRT
Phase 3
Nivolumab + Chemotherapy ± BMS-986012
Anti–PD-1 + Chemotherapy ± Anti–FucGM1
Area of Research: 1L ES-SCLC
Phase 2
Nivolumab + Chemotherapy ± Relatlimab
Anti–PD-1 + Chemotherapy ± Anti–LAG-3
Area of Research: 1L Stage IV or Recurrent NSCLC
Phase 2
Nivolumab + Ipilimumab ± BMS-986207
Anti–PD-1 + Anti–CTLA-4 ± Anti-TIGIT
Area of Research: 1L Stage IV NSCLC
Phase 2
Expand All Displaying 5 of 11
Lung
No trials are available at this time. Check back for updates.
Melanoma
BMS-986213
Anti–PD-1 ± Anti–LAG-3
Area of Research: Completely Resected Stage III-IV Melanoma
Phase 3
Ipilimumab + Relatlimab
Anti–CTLA-4 ± Anti–LAG-3
Area of Research: Advanced or Unresectable Melanoma Patients Who Have Progressed on/After Anti–PD-L1 Therapy
Phase 1/2
Nivolumab ± HyaluronidaseAnti–PD-1 ± Hyaluronidase
Area of Research: Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma
Phase 3
Expand All Displaying 5 of 11
Melanoma
No trials are available at this time. Check back for updates.
Mesothelioma
Nivolumab + Ipilimumab
Anti–PD-1 + Anti–CTLA-4
Area of Research: Unresectable Pleural Mesothelioma
Phase 2
Expand All Displaying 5 of 11
Mesothelioma
No trials are available at this time. Check back for updates.
Prostate
BMS-986218 + Chemotherapy ± Nivolumab
Anti–CTLA-4–NF + Chemotherapy ± Anti–PD-1
Area of Research: Metastatic CRPC
Phase 2
BMS-986218 ± Nivolumab
Anti–CTLA-4–NF + Anti–PD-1
Area of Research: Metastatic CRPC
Phase 2
CC-90011 + Anti-Androgen + Steroid
LSD1 Inhibitor + Anti-Androgen + Steroid
Area of Research: Metastatic CRPC
Phase 1
Nivolumab + Chemotherapy + Steroid
Anti–PD-1 + Chemotherapy + Steroid
Area of Research: 2L+ mCRPC
Phase 3
Expand All Displaying 5 of 11
Prostate
No trials are available at this time. Check back for updates.
Renal Cell Carcinoma
Nivolumab + Ipilimumab
Anti–PD-1 + CTLA-4
Area of Research: Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk Factors
Phase 4
Nivolumab ± HyaluronidaseAnti–PD-1
Area of Research: Advanced or mccRCC
Phase 3
Expand All Displaying 5 of 11
Renal Cell Carcinoma
No trials are available at this time. Check back for updates.
Solid Tumors
AGEN1777 ± Anti–PD-1TIGIT Bispecific ± Anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1
BMS-986207 + Nivolumab ± Ipilimumab
Anti-TIGIT + Anti–PD-1 ± Anti–CTLA-4
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986213
Anti–PD-1 + Anti–LAG-3
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986218 ± Nivolumab
Anti–CTLA-4–NF ± Anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986249 ± Nivolumab
Anti–CTLA-4 Probody ± Anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986253 + Nivolumab ± Ipilimumab
Anti–IL-8 + Anti–PD-1 ± Anti–CTLA-4
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986288 ± Nivolumab
Anti–CTLA-4–NF Probody ± Anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986301 ± Nivolumab + Ipilimumab
STING Agonist ± Anti–PD-1 + Anti–CTLA-4
Area of Research: Advanced Solid Tumors
Phase 1
BMS-986315 ± EGFR Inhibitor
Anti-NKG2A ± EGFR Inhibitor
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986315 ± Nivolumab
Anti-NKG2A ± Anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986340 ± Nivolumab
Anti-CCR8 ± Anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986415 ± NivolumabIL-12 Fc ± Anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986416 ± Nivolumab
TGFβi ± Anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1
CC-95251 + Anti–CD-20
Anti-SIRPα + Anti–CD-20
Area of Research: Advanced Solid Tumors
Phase 1
CC-95251 + EGFR Inhibitor
Anti-SIRPα + EGFR Inhibitor
Area of Research: Advanced Solid Tumors
Phase 1
IK-175 ± NivolumabAHR Antagonist ± Anti–PD-1
Area of Research: Advanced Solid Tumors and UC
Phase 1
Nivolumab ± HyaluronidaseAnti–PD-1 ± Hyaluronidase
Area of Research: Advanced Solid Tumors
Phase 1/2
Nivolumab
Anti–PD-1
Area of Research: Pan-tumor Study for Long-term Follow-up
Phase 2
Relatlimab + Nivolumab + Ipilimumab
Anti–LAG-3 + Anti–PD-1 + Anti–CTLA-4
Area of Research: Advanced Solid Tumors
Phase 1/2
Expand All Displaying 5 of 11
Solid Tumors (General)
No trials are available at this time. Check back for updates.
Looking for more clinical trials?
Bolder Science contains all clinical trials available on ClinicalTrials.gov, including BMS trials.
Visit BolderScience.com to search all trials worldwide.
Powered by ClinicalTrials.gov
Log In
Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.
Please enter your email address.
You will receive a link to create a new password via email.
Create Account
Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.
